2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 Potently Stimulates Gene-specific DNA Binding of the Vitamin D Receptor in Osteoblasts*
暂无分享,去创建一个
[1] S. Peleg,et al. 2α-(3-Hydroxypropyl)- and 2α-(3-Hydroxypropoxy)-1α,25-dihydroxyvitamin D3 Accessible to Vitamin D Receptor Mutant Related to Hereditary Vitamin D-Resistant Rickets , 2003 .
[2] N. Kubodera,et al. A new active vitamin D analog, ED‐71, causes increase in bone mass with preferential effects on bone in osteoporotic patients , 2003, Journal of cellular biochemistry.
[3] C. Carlberg. Molecular basis of the selective activity of vitamin D analogues , 2003, Journal of cellular biochemistry.
[4] J. Pike,et al. Inhibition of 1,25‐Dihydroxyvitamin D3‐Dependent Transcription by Synthetic LXXLL Peptide Antagonists that Target the Activation Domains of the Vitamin D and Retinoid X Receptors , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[5] G. Buchanan,et al. A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. , 2002, Molecular endocrinology.
[6] H. DeLuca,et al. A potent analog of 1α,25-dihydroxyvitamin D3 selectively induces bone formation , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[7] C. Der,et al. Role of MAP Kinases in the 1,25-Dihydroxyvitamin D3-induced Transactivation of the Rat Cytochrome P450C24 (CYP24) Promoter , 2002, The Journal of Biological Chemistry.
[8] J. Pike,et al. Vitamin D receptor-mediated gene regulation mechanisms and current concepts of vitamin D analog selectivity. , 2002, Advances in renal replacement therapy.
[9] P. Farnham,et al. Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation. , 2002, Methods.
[10] M. Galligan,et al. Distinct retinoid X receptor activation function-2 residues mediate transactivation in homodimeric and vitamin D receptor heterodimeric contexts. , 2001, Journal of molecular endocrinology.
[11] D. Moras,et al. Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[12] Myles Brown,et al. Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription , 2000, Cell.
[13] M Carlquist,et al. Structural aspects of agonism and antagonism in the oestrogen receptor. , 2000, Biochemical Society transactions.
[14] J. Pike,et al. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[15] C. Carlberg,et al. Response element and coactivator-mediated conformational change of the vitamin D(3) receptor permits sensitive interaction with agonists. , 2000, Molecular pharmacology.
[16] Alex J. Brown,et al. Mechanisms for the selective actions of vitamin D analogues. , 2000, Current pharmaceutical design.
[17] B. O’Malley,et al. Phosphorylation of Steroid Receptor Coactivator-1 , 2000, The Journal of Biological Chemistry.
[18] Sundeep Khosla,et al. The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[19] D. Fowlkes,et al. Dissection of the LXXLL Nuclear Receptor-Coactivator Interaction Motif Using Combinatorial Peptide Libraries: Discovery of Peptide Antagonists of Estrogen Receptors α and β , 1999, Molecular and Cellular Biology.
[20] S. Morony,et al. A Chimeric Form of Osteoprotegerin Inhibits Hypercalcemia and Bone Resorption Induced by IL‐1β, TNF‐α, PTH, PTHrP, and 1,25(OH)2D3 , 1999 .
[21] L. Freedman,et al. 20-Epi Analogues of 1,25-Dihydroxyvitamin D3 Are Highly Potent Inducers of DRIP Coactivator Complex Binding to the Vitamin D3 Receptor* , 1999, The Journal of Biological Chemistry.
[22] R. K. DeLisle,et al. The Autonomous Transactivation Domain in Helix H3 of the Vitamin D Receptor Is Required For Transactivation and Coactivator Interaction* , 1999, The Journal of Biological Chemistry.
[23] P. Mäenpää,et al. Structure-function studies of new C-20 epimer pairs of vitamin D3 analogs. , 1999, European journal of biochemistry.
[24] B. O’Malley,et al. Proteasome-dependent degradation of the human estrogen receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[25] David A. Agard,et al. The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.
[26] H. Masuyama,et al. Proteasome‐mediated degradation of the vitamin D receptor (VDR) and a putative role for SUG1 interaction with the AF‐2 domain of VDR , 1998, Journal of cellular biochemistry.
[27] H. DeLuca,et al. New 1alpha,25-dihydroxy-19-norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues. , 1998, Journal of medicinal chemistry.
[28] H. DeLuca,et al. Current understanding of the molecular actions of vitamin D. , 1998, Physiological reviews.
[29] M. Haussler,et al. The Nuclear Vitamin D Receptor: Biological and Molecular Regulatory Properties Revealed , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[30] R. Baron,et al. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[31] M. Elgort,et al. Retinoid X Receptor (RXR) Ligands Activate the Human 25-Hydroxyvitamin D3-24-hydroxylase Promoter via RXR Heterodimer Binding to Two Vitamin D-responsive Elements and Elicit Additive Effects with 1,25-Dihydroxyvitamin D3 * , 1997, The Journal of Biological Chemistry.
[32] David M. Heery,et al. A signature motif in transcriptional co-activators mediates binding to nuclear receptors , 1997, Nature.
[33] L. Binderup,et al. Development of new vitamin D analogs , 1997 .
[34] A. Norman,et al. Distinct Conformational Changes Induced by 20-epi Analogues of 1,25-Dihydroxyvitamin D Are Associated with Enhanced Activation of the Vitamin D Receptor (*) , 1995, The Journal of Biological Chemistry.
[35] D. Bikle. Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential. , 1992, Endocrine reviews.
[36] D. Edwards,et al. Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. , 1992, The Journal of biological chemistry.
[37] J. Pike,et al. Vitamin D receptor interaction with specific DNA. Association as a 1,25-dihydroxyvitamin D3-modulated heterodimer. , 1991, The Journal of biological chemistry.
[38] L. Binderup,et al. Calcipotriol (MC 903): pharmacokinetics in rats and biological activities of metabolites. A comparative study with 1,25(OH)2D3. , 1991, Biochemical pharmacology.
[39] K. Ozono,et al. The vitamin D-responsive element in the human osteocalcin gene. Association with a nuclear proto-oncogene enhancer. , 1990, The Journal of biological chemistry.
[40] J. Haddad,et al. Vitamin D binding protein (Gc-globulin). , 1989, Endocrine reviews.
[41] B. O’Malley,et al. Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. , 1988, Science.
[42] M. Haussler,et al. Association of 1,25-dihydroxyvitamin D3 with cultured 3T6 mouse fibroblasts. Cellular uptake and receptor-mediated migration to the nucleus. , 1983, The Journal of biological chemistry.
[43] M. Haussler,et al. Serum and monoclonal antibodies against the chick intestinal receptor for 1,25-dihydroxyvitamin D3. Generation by a preparation enriched in a 64,000-dalton protein. , 1983, The Journal of biological chemistry.
[44] P. Holland,et al. Inactivation of pig heart thiolase by 3-butynoyl coenzyme A, 3-pentynoyl coenzyme A, and 4-bromocrotonyl coenzyme A. , 1973, Biochemistry.
[45] D. Moras,et al. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. , 2000, Molecular cell.
[46] H. DeLuca,et al. Modern view of vitamin D3 and its medicinal uses. , 1998, Progress in medicinal chemistry.